Results 121 to 130 of about 119,169 (307)
Background: CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents.
Nithya Krishnamurthy +9 more
doaj +1 more source
Evolving clinical profile of IL-1β, IL-10 and CTLA-4 gene in rheumatoid factor positive Caucasian population [PDF]
Rheumatoid arthritis (RA), a systemic autoimmune condition, causes joint damage and sometimes extra-articular lesions (cutaneous vasculitis, neuropathy, Felty’s syndrome, pericarditis, intersticial lung disease) that may be life threatening.
Anupama Sharma, Ajay kumar Singh, Sanjeev kumar Singh, Neelima Singh, Varsha Gupta, Int J Cur Bio Med Sci.
core
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello +3 more
core +1 more source
Engineered mesoporous silica nanoparticles (Silicasomes) enable systemic delivery of the STING agonist ADU‐S100, overcoming the instability and toxicity that limit cyclic dinucleotides to local administration. By enhancing tumor accumulation, activating systemic antitumor immunity, and remodeling the tumor immune microenvironment, these nanoparticles ...
Wenjing Zhou +10 more
wiley +1 more source
ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li +8 more
wiley +1 more source
Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. [PDF]
Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhibitors (ICIs) including, but not limited to ...
Adashek, Jacob J +3 more
core
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley +1 more source
ABSTRACT Mass cytometry is optimal for acute leukemia immune checkpoint profiling. However, current commercial metal‐chelating polymer (MCP) metal tags limit its sensitivity due to low metal loading capacity. We report a novel synthetic strategy employing antibody‐conjugated gold or platinum nanoparticles (AuNP/PtNP) for high‐dimensional single‐cell ...
Zhizhou Liu +8 more
wiley +1 more source
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source
Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang +4 more
wiley +1 more source

